Regulus Therapeutics Inc.
RGLS
Classificação em ações
#17275
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Preço da ação
$8.16
Última sincronização: 2025-06-26
Valor de mercado
$234.57M
Variação (1 dia)
0.00%
Variação (1 ano)
-56.96%
País
US
Negociar Regulus Therapeutics Inc. (RGLS)
Categoria
Healthcare
Histórico de preços das ações de Regulus Therapeutics Inc. (RGLS)
Preço de fecho mais alto: $18.90 em 2024-08-01
Preço de fecho mais baixo: $25.97 em 2018-04-01
Preço de fecho mais baixo: $25.97 em 2018-04-01
Histórico de preços das ações da Regulus Therapeutics Inc. de 2018 a 2026
Desempenho anual do preço das ações
| Ano | Desempenho |
|---|---|
| 2024 | 115.52% |
| 2023 | 128.77% |
| 2022 | -59.49% |
| 2021 | -66.20% |
| 2020 | -18.96% |
| 2019 | 28.12% |
| 2018 | 0.00% |
Preço das ações de empresas similares ou concorrentes
| Empresa | Preço da ação | Variação 1a% | País |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
